Minneapolis Startup OneOme Expands Into Asia

sourced

Categories

Via News Release

“MINNEAPOLIS, HONG KONG (September 13, 2017) – Today, OneOme and Rainbow Genomics announced they are teaming up to provide genomic services to patients in Hong Kong, Japan, and Macau. OneOme’s RightMed® pharmacogenomic test will be offered alongside Rainbow Genomics’ whole exome sequencing test services. The full OneOme RightMed platform – which identifies how a patient’s DNA and current medications may affect their response to drugs – will be offered by Rainbow Genomics to patients and physicians.”

Read More »

Minnesota HealthTech Startup OneOme Enters The Canadian Marketplace

sourced

Categories

Via News Release

“MINNEAPOLIS and NORTH BAY, Ontario, July 26, 2017 /PRNewswire/ — A new partnership between OneOme and ProZed Pharmacy Solutions brings the power of personalized medicine to Canada. Minnesota-based OneOme will provide its RightMed® pharmacogenomics platform exclusively to customers of ProZed Pharmacy Solutions at Northern Shores Pharmacy in North Bay, Ontario as the first step in a nationwide launch. The partnership is the precision medicine company’s first entry into the Canadian retail pharmacy market.”

Read More »

OneOme Expands Reach To Five More States

sourced

Categories

By Burl Gilyard, Twin Cities Business

“Minneapolis-based medical startup OneOme continues to raise its profile in the emerging pharmacogenomics industry. On Monday, the company announced that it had earned laboratory certification allowing it to start offering its RightMed test in five additional states: California, Florida, Maryland, Pennsylvania and Rhode Island. OneOme is now able to offer its testing technology in every state except New York, where it is seeking to obtain laboratory certification this year.”

Read More…

[UPDATED] Mayo-Backed Personalized Medicine Startup OneOme Raises $5.25m

oo_logo

[Updated 10/4 @4:30 CST – OneOme CFO Mark Sylvester says the oversubscribed round is closed at $5.25m and the company is actively selling into the market now]

Minneapolis-based OneOme has raised $530k of a $600k equity funding round, according to this SEC disclosure.

Formed in 2013, OneOme works with physicians who place orders for patient test kits that the physician administers or are sent to directly the patient and back to the lab for DNA and  bioinformatics analysis. This generates a personalized pharmacogenomic report in under 2 weeks at a cost of $249. Soon,  this process will be integrated directly into the EMR experience.

Read More »

Big Data Genomics Startup OneOme Quietly Raises More Cash

Screen Shot 2015-08-05 at 8.03.11 AMOneOme, the product of a partnership between the Mayo Clinic & Invenshure, continues to raise early stage capital for their prescription medicine efficiency platform.

“OneOme analyzes patient DNA via the most complex multi-gene algorithm in the marketplace. Working with physicians and health care providers, we minimize errors and failures and advance efficacy and safety. Applied across the majority of pharmaceutical medicine, the result is an actionable, at-a-glance prescription recommendation report that is absolutely personalized to each patient. The next level of pharmaceutical efficiency and safety is here. “

Read More »

Mayo and Invenshure launch genomics platform Oneome

sourced

Categories

Via News Release

“ROCHESTER, Minn. — Mayo Clinic and venture catalyst Invenshure announce the launch of Oneome, a genomics interpretation company that exports Mayo’s extensive pharmacogenomics knowledge in the form of concise, actionable reports to help providers anywhere deliver the right medication at the right time.”

Read More…

Post Navigation